

ForPatients

by Roche

Non-Small Cell Lung Cancer (NSCLC)

The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT03559647 ML39885

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

Hyperion Is A Prospective, Multicenter, Non-Interventional, Two-Cohort Study Collecting Primary Data In Patients With Locally Advanced Or Metastatic NSCLC Of Squamous Or Non-Squamous Histology After Prior Chemotherapy Being Treated With Atezolizumab In Routine Clinical Practice.

Hoffmann-La Roche
Sponsor

N/A
Phase

NCT03559647 ML39885
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥ 18 Years

Healthy Volunteers
No
